Stock listing

NASDAQ:BDTX Black Diamond Therapeutics, Inc. Stock

Home listing (NASDAQ) of Black Diamond Therapeutics, Inc.

Follow Black Diamond Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:BDTX

$1.31 USD -0.12 (-8.4%)

Close on Nov 20, 2026

Past year -65.6% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.31 – $1.41 USDNov 20, 2026
Volume
663,186 sharesNov 20, 2026
Market cap
$75.28M USDAt the close on Nov 20, 2026 · price × 57.47M shares outstanding
52-week range
$1.31 – $3.97 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$1.32M USDMedian day 613,500 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Black Diamond Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:BDTX · Home$1.31 USD-0.12 (-8.4%)663,186$1.33$1.41$1.31$1.43Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:BDTX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.31-0.12-8.4%$1.33$1.41$1.31663,186
$1.43-0.01-0.7%$1.42$1.46$1.39603,018
$1.44-0.09-5.9%$1.50$1.529$1.391645,967
$1.53+0.06+4.1%$1.46$1.53$1.40708,747
$1.47-0.05-3.3%$1.55$1.57$1.45896,661
$1.52-0.09-5.6%$1.61$1.635$1.51956,159
$1.61+0.015+0.9%$1.68$1.689$1.58852,310
$1.595-0.265-14.2%$1.90$1.91$1.581,401,003
$1.86+0.125+7.2%$1.76$1.905$1.745730,430
$1.735+0.075+4.5%$1.65$1.79$1.64432,083
$1.66-0.24-12.6%$1.89$1.90$1.65562,281
$1.90+0.09+5.0%$1.86$1.96$1.84607,514
$1.81+0.06+3.4%$1.76$1.85$1.76331,799
$1.75-0.03-1.7%$1.79$1.86$1.75493,685
$1.78-0.08-4.3%$1.86$1.90$1.76515,418
$1.86+0.03+1.6%$1.85$1.89$1.795548,804
$1.83+0.08+4.6%$1.74$1.87$1.7051,043,391
$1.75+0.06+3.6%$1.71$1.77$1.6451,099,234
$1.69-0.19-10.1%$1.90$1.90$1.67861,132
$1.88-0.20-9.6%$2.05$2.05$1.83927,726
$2.080.000.0%$2.06$2.105$2.03790,955
$2.08+0.01+0.5%$2.07$2.14$2.0052,355,483
$2.07+0.26+14.4%$1.82$2.14$1.822,113,789
$1.81+0.09+5.2%$1.71$1.835$1.71825,582
$1.72-0.02-1.1%$1.75$1.75$1.675539,800
$1.74+0.04+2.4%$1.69$1.74$1.67624,700
$1.70+0.02+1.2%$1.67$1.76$1.631,069,400
$1.68-0.09-5.1%$1.76$1.77$1.601,141,000
$1.77-0.06-3.3%$1.865$1.865$1.765377,700
$1.83+0.02+1.1%$1.81$1.83$1.79448,800
$1.81-0.02-1.1%$1.81$1.81$1.77785,000
$1.83+0.03+1.7%$1.79$1.87$1.775563,300
$1.80-0.14-7.2%$1.94$1.96$1.795839,100
$1.94+0.05+2.6%$1.90$1.95$1.875838,600
$1.89+0.01+0.5%$1.91$1.94$1.875472,200
$1.88-0.005-0.3%$1.88$1.90$1.84399,100
$1.885+0.015+0.8%$1.89$1.93$1.845551,800
$1.87+0.04+2.2%$1.84$1.89$1.825440,200
$1.83-0.05-2.7%$1.89$1.89$1.81648,300
$1.88-0.01-0.5%$1.91$1.915$1.85378,300
$1.89-0.01-0.5%$1.90$1.915$1.83459,700
$1.90-0.08-4.0%$1.97$1.97$1.85613,500
$1.98+0.03+1.5%$1.93$1.995$1.90743,900
$1.95-0.01-0.5%$1.96$1.97$1.91827,100
$1.96+0.03+1.6%$1.91$1.96$1.911,178,500
$1.93-0.01-0.5%$1.98$2.02$1.92665,300
$1.94-0.03-1.5%$1.97$2.007$1.915733,900
$1.97-0.06-3.0%$2.02$2.02$1.94301,800
$2.03+0.05+2.5%$1.98$2.04$1.97514,100
$1.98+0.02+1.0%$1.99$2.00$1.94589,100
$1.96-0.14-6.7%$2.06$2.06$1.92676,100
$2.100.000.0%$2.09$2.149$2.065402,400
$2.10-0.02-0.9%$2.09$2.13$2.072367,200
$2.12+0.02+1.0%$2.08$2.145$2.061323,700
$2.10-0.04-1.9%$2.15$2.166$2.06609,800
$2.14+0.10+4.9%$2.08$2.155$2.05561,300
$2.04-0.06-2.9%$2.09$2.11$2.02759,100
$2.10-0.13-5.8%$2.22$2.225$2.10507,000
$2.23-0.04-1.8%$2.28$2.29$2.17521,900
$2.270.000.0%$2.26$2.32$2.24457,600
$2.27+0.03+1.3%$2.21$2.29$2.16491,300
$2.24+0.085+3.9%$2.19$2.245$2.185417,500
$2.155-0.055-2.5%$2.22$2.22$2.13345,000
$2.21+0.06+2.8%$2.15$2.26$2.15656,600
$2.15-0.04-1.8%$2.17$2.19$2.081,137,800
Ticker
NASDAQ:BDTX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Black Diamond Therapeutics, Inc. news

Black Diamond Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
13 in the last 12 months · 100 in all · newest Nov 12, 2026 · oldest 2020
Decks
8 decks · latest Dec 3, 2025

Where Black Diamond Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:BDTX · Home listing · This pageNASDAQUnited StatesUSD
BOATS:BDTXBOATSUnited StatesUSD

Valuation

Price/book 0.8× against a median of 2.4×: 2nd lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$10.71M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.8×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.2×
Beta vs S&P 500
1.76

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Black Diamond Therapeutics, Inc. · NASDAQ:BDTXUS$75.28M−US$10.71Mn/an/an/a0.8×n/a0.2×1.76
TiumBio Co., Ltd. · KRX:321550US$77.24MUS$60.57Mn/a5.4×n/a2.9×−114.1%0.3×n/a
HLB Therapeutics Co., Ltd. · KRX:115450US$76.82MUS$66.93Mn/a1.4×n/a0.7×−28.0%0.0×n/a
Recce Pharmaceuticals Ltd. · ASX:RCEUS$75.90MUS$81.02Mn/an/an/an/an/an/an/a
Great Novel Therapeutics Biotech & Medicals Corp. · TPEX:7427US$73.93MUS$52.73Mn/a1,442×n/a3.2×n/a0.0×n/a
Pentixapharm Holding AG · XETR:PTPUS$73.87MUS$69.92Mn/a1,158×n/a2.4×n/a0.0×n/a
Dimerix Limited · ASX:DXBUS$73.52MUS$62.98Mn/a21.9×n/an/a−685.3%n/an/a
Faron Pharmaceuticals Oy · LSE:FARNUS$72.99MUS$57.36Mn/an/an/a5.7×n/a1.5×n/a
Kanaph Therapeutics Inc. · KRX:0082N0US$72.81MUS$39.07Mn/a9.3×n/a2.1×−729.8%0.0×n/a
Cellectis S.A. · EURONEXT:ALCLSUS$72.64M−US$9.64Mn/a−0.2×n/a1.8×−115.4%2.1×n/a
Eastwood Bio-Medical Canada Inc · TSXV:EBMUS$72.06MUS$72.05Mn/a127×n/an/a−28.5%n/a0.56
Median of the othersUS$73.69MUS$61.78M15.6×2.4×−114.7%0.0×0.56

Forecasts

5 strong buy · 2 buy · 1 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
10.86 USD · Analysts' mean
EPS, year to Dec 2026
-0.68 · 5 analysts

Team and board

Officers

OfficerRole
Mark A. VellecaChief Executive Officer
Prakash RamanCEO of InduPro, Inc.
Samarth KulkarniCEO, CRISPR Therapeutics AG
Brent Hatzis-SchochChief Operating Officer, General Counsel
Erika JonesSenior Vice President of Finance and Principal Financial & Accounting Officer
Ali BehbahaniCo-Head of Healthcare, NEA
Elizabeth BuckCo-Founder, Chief Scientific Officer
Melanie MorrisonChief Development Officer
Sergey YurasovChief Medical Officer

Board

DirectorRole
Mark A. VellecaChief Executive Officer
Ali BehbahaniCo-Head of Healthcare, NEA
Garry E. MenzelOperating Partner, GHO Capital Partners LLP
Kapil DhingraDirector
Prakash RamanCEO of InduPro, Inc.
Samarth KulkarniCEO, CRISPR Therapeutics AG
Shannon CampbellDirector

Events

QuarterResultsShare move
Q3 2026Nov 10, 2026 · Before open−14.3%
Q2 2026Aug 5, 2026 · After close+7.3%
Q1 2026May 7, 2026 · Before open−3.5%
Q4 2025Mar 18, 2026−3.6%
Q3 2025Nov 6, 2025 · Before open+2.8%
Q2 2025Aug 7, 2025 · Before open−15.2%
Q1 2025May 12, 2025 · After close+10.3%
Q4 2024Mar 10, 2025 · Before open−9.0%
Q3 2024Nov 5, 2024 · Before open+8.7%
Q2 2024Aug 6, 2024 · Before open−5.6%
All 20 quarters
QuarterResultsShare move
Q1 2024May 9, 2024 · Before open−2.7%
Q4 2023Mar 12, 2024 · Before open−5.5%
Q3 2023Nov 6, 2023 · Before open+0.5%
Q2 2023Aug 11, 2023 · Before open−2.4%
Q1 2023May 9, 2023 · Before open−5.2%
Q4 2022Mar 9, 2023 · Before open−13.7%
Q3 2022Nov 8, 2022 · Before open+3.2%
Q2 2022Aug 9, 2022 · Before open+0.8%
Q1 2022May 11, 2022 · After close−1.6%
Q4 2021Mar 17, 2022 · After close+5.0%

Open Events

Decks

DeckKindSlidesDate
Corporate Update (December 2025)Corporate update38 slidesDec 3, 2025
Investor Presentation (March 2025)Investor deck38 slidesMar 19, 2025
AACR Annual Meeting 2024Conference15 slidesApr 5, 2024
Investor Presentation (January 2024)Investor deck42 slidesJan 4, 2024
Investor Presentation (April 2022)Investor deck38 slidesApr 25, 2022
Investor Presentation (January 2022)Investor deck39 slidesJan 10, 2022
Technical Presentation (2021)Technical10 slides2021
32nd EORTC-NCI-AACR Virtual Symposium 2020Conference13 slidesOct 24, 2020

Open Decks

IPO

Priced at US$19.00 a share on Jan 29, 2020.

Price
US$19.00 a share
Shares offered
10,586,316 shares of common stock
Offering size
US$201.1 million
Underwriters' option
Up to 1,587,947 more shares
Underwriters
J.P. Morgan, Jefferies, Cowen, Canaccord Genuity · In the order on the cover
Shares delivered
On or about Feb 3, 2020

Steps

StepWhen
Draft sent to the SEC in confidenceAug 23, 2019
Filed publiclyJan 3, 2020
Amended onceJan 21, 2020
Shares registered with an exchangeJan 27, 2020
Declared effective by the SECJan 29, 2020
Final prospectus, with the priceJan 30, 2020

Open IPO · From the cover of the final prospectus (424B4) filed Jan 30, 2020

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue70.0M00000000
Cost of revenue325.0K343.0K437.0K3.24M2.22M600.0K47.0K44.0K24.0K
Gross profit69.7M-343.0K-437.0K-3.24M-2.22M-600.0K-47.0K-44.0K-24.0K
Research and development33.6M51.3M59.4M64.4M96.8M48.2M21.8M6.95M3.45M
Selling, general and administrative16.6M27.5M27.1M28.4M30.0M21.4M7.58M1.95M666.0K
Operating income12.5M-78.8M-86.5M-92.8M-126.9M-69.6M-29.3M-8.90M-4.12M
Depreciation and amortization325.0K343.0K437.0K508.0K205.0K52.0K47.0K44.0K24.0K
EBITDA12.8M-78.4M-86.0M-92.3M-126.7M-69.5M-29.3M-8.86M-4.09M
Interest expense3.91M01.00K0065.0K
Income before tax22.4M-69.7M-82.6M-91.3M-125.3M-67.0M-35.3M-8.93M-4.60M
Income tax0000000059.0K
Net income22.4M-69.7M-82.4M-91.2M-125.6M-67.3M-35.3M-8.93M-4.60M
Earnings per share, basic0.39-1.27-1.88-2.52-3.47-2.05-16.99-4.42-0.64
Earnings per share, diluted0.39-1.27-1.88-2.52-3.47-2.05-16.99-4.42

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents21.0M36.4M56.2M34.3M65.8M34.6M154.7M51.7M7.88M
Short-term investments107.7M62.1M75.2M88.5M144.0M280.5M0
Current assets132.4M101.2M134.0M127.7M215.7M319.6M155.7M51.7M7.91M
Property, plant and equipment365.0K1.39M1.73M2.59M3.04M385.0K164.0K134.0K102.0K
Total assets143.0M122.6M158.6M156.3M247.7M329.7M158.3M51.8M8.02M
Accounts payable579.0K4.01M2.32M1.88M4.11M2.54M1.96M416.0K152.0K
Current liabilities15.7M20.6M19.6M15.3M23.6M14.2M4.86M2.58M2.23M
Total debt18.8M22.2M25.3M28.1M28.5M8.74M200.6M60.8M12.5M
Total liabilities30.8M39.4M41.8M40.6M51.8M21.9M4.88M6.60M14.7M
Shareholders' equity112.2M83.3M116.7M115.7M195.9M307.8M-47.2M-15.5M-6.67M
Shares outstanding57.1M56.6M51.6M36.4M36.2M36.1M2.24M2.17M7.20M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations29.6M-62.3M-66.7M-85.1M-100.1M-52.1M-24.7M-8.45M-2.35M
Capital spending00-33.0K-192.0K-2.71M-142.0K-21.0K-76.0K-77.0K
Free cash flow29.6M-62.3M-66.8M-85.3M-102.9M-52.3M-24.7M-8.53M-2.43M
Cash from investing-44.9M17.0M16.3M53.4M130.6M-281.7M-21.0K-76.0K-77.0K
Cash from financing-146.0K25.5M71.9M177.0K729.0K214.9M127.8M52.3M9.97M
Share buybacks177.0K729.0K214.9M129.5M52.3M10.0M
Change in cash-15.4M-19.8M21.6M-31.5M31.2M-118.9M103.1M43.8M7.55M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 10, 2026Quarterly reportSEC
8-K · Current reportNov 10, 2026ResultsSEC
4 · Change in ownershipSep 21, 2026Insider tradeSEC
4 · Change in ownershipSep 21, 2026Insider tradeSEC
10-Q · Quarterly reportAug 5, 2026Quarterly reportSEC
8-K · Current reportAug 5, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeJul 27, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 8, 2026Big-stake noticeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
8-K · Current reportJun 29, 2026Meeting outcomeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
8-K · Current reportMay 21, 2026Current reportSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
8-K · Current reportMay 7, 2026ResultsSEC
ARS · Annual report to shareholdersApr 29, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2026Meeting noticeSEC
4 · Change in ownershipMar 20, 2026Insider tradeSEC
4 · Change in ownershipMar 20, 2026Insider tradeSEC
S-8 · Registration statement for employee plansMar 16, 2026Offer documentSEC
10-K · Annual reportMar 16, 2026Annual reportSEC
8-K · Current reportMar 16, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
4 · Change in ownershipJan 23, 2026Insider tradeSEC
4 · Change in ownershipJan 23, 2026Insider tradeSEC
4 · Change in ownershipJan 23, 2026Insider tradeSEC
4 · Change in ownershipJan 23, 2026Insider tradeSEC
4 · Change in ownershipJan 23, 2026Insider tradeSEC
4 · Change in ownershipDec 15, 2025Insider tradeSEC
4 · Change in ownershipDec 15, 2025Insider tradeSEC
EFFECT · Notice that a registration is effectiveDec 4, 2025Other filingsSEC
8-K · Current reportDec 3, 2025ResultsSEC
CORRESP · Letter to the SECDec 1, 2025Other filingsSEC
S-3 · Registration statementNov 13, 2025Offer documentSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
4 · Change in ownershipSep 22, 2025Insider tradeSEC
4 · Change in ownershipSep 22, 2025Insider tradeSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
8-K · Current reportAug 7, 2025ResultsSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
8-K · Current reportJun 12, 2025Meeting outcomeSEC
10-Q · Quarterly reportMay 12, 2025Quarterly reportSEC
8-K · Current reportMay 12, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 29, 2025Big-stake noticeSEC
ARS · Annual report to shareholdersApr 18, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 18, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 18, 2025Meeting noticeSEC
4 · Change in ownershipMar 21, 2025Insider tradeSEC
4 · Change in ownershipMar 21, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 21, 2025Big-stake noticeSEC
4 · Change in ownershipMar 20, 2025Insider tradeSEC
8-K · Current reportMar 19, 2025Material contractSEC
S-8 · Registration statement for employee plansMar 6, 2025Offer documentSEC
10-K · Annual reportMar 6, 2025Annual reportSEC
8-K · Current reportMar 6, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
4 · Change in ownershipJan 31, 2025Insider tradeSEC
4 · Change in ownershipJan 31, 2025Insider tradeSEC
4 · Change in ownershipJan 31, 2025Insider tradeSEC
4 · Change in ownershipJan 31, 2025Insider tradeSEC
4 · Change in ownershipJan 31, 2025Insider tradeSEC
4 · Change in ownershipDec 16, 2024Insider tradeSEC
4 · Change in ownershipDec 16, 2024Insider tradeSEC
4 · Change in ownershipDec 16, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 8, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 5, 2024Quarterly reportSEC
8-K · Current reportNov 5, 2024ResultsSEC
SC 13G · Big-stake noticeOct 24, 2024Big-stake noticeSEC
8-K · Current reportOct 7, 2024Management or board changeSEC
8-K · Current reportSep 23, 2024Current reportSEC
4 · Change in ownershipSep 20, 2024Insider tradeSEC
4 · Change in ownershipSep 20, 2024Insider tradeSEC
4 · Change in ownershipSep 20, 2024Insider tradeSEC
4 · Change in ownershipAug 30, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedAug 8, 2024Big-stake noticeSEC
10-Q · Quarterly reportAug 6, 2024Quarterly reportSEC
8-K · Current reportAug 6, 2024ResultsSEC
144 · Notice of proposed saleJul 31, 2024Other filingsSEC
144 · Notice of proposed saleJul 26, 2024Other filingsSEC
144 · Notice of proposed saleJul 16, 2024Other filingsSEC
144 · Notice of proposed saleJul 11, 2024Other filingsSEC
SC 13G/A · Big-stake notice, amendedJul 10, 2024Big-stake noticeSEC
144 · Notice of proposed saleJul 9, 2024Other filingsSEC
144 · Notice of proposed saleJun 28, 2024Other filingsSEC
144 · Notice of proposed saleJun 27, 2024Other filingsSEC
144 · Notice of proposed saleJun 26, 2024Other filingsSEC
144 · Notice of proposed saleJun 24, 2024Other filingsSEC
144 · Notice of proposed saleJun 21, 2024Other filingsSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
144 · Notice of proposed saleJun 20, 2024Other filingsSEC
144 · Notice of proposed saleJun 20, 2024Other filingsSEC
144 · Notice of proposed saleJun 18, 2024Other filingsSEC
144 · Notice of proposed saleJun 14, 2024Other filingsSEC
144 · Notice of proposed saleJun 13, 2024Other filingsSEC
144 · Notice of proposed saleJun 12, 2024Other filingsSEC
4 · Change in ownershipJun 6, 2024Insider tradeSEC
4 · Change in ownershipJun 6, 2024Insider tradeSEC
4 · Change in ownershipJun 6, 2024Insider tradeSEC
4 · Change in ownershipJun 6, 2024Insider tradeSEC
4 · Change in ownershipJun 6, 2024Insider tradeSEC
4 · Change in ownershipJun 6, 2024Insider tradeSEC
8-K · Current reportJun 6, 2024Meeting outcomeSEC
SC 13D/A · Big-stake notice, amendedMay 13, 2024Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedMay 9, 2024Big-stake noticeSEC
10-Q · Quarterly reportMay 9, 2024Quarterly reportSEC
8-K · Current reportMay 9, 2024ResultsSEC
ARS · Annual report to shareholdersApr 24, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 24, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 24, 2024Meeting noticeSEC
4 · Change in ownershipApr 12, 2024Insider tradeSEC
4 · Change in ownershipApr 12, 2024Insider tradeSEC
3 · Initial statement of ownershipApr 12, 2024Insider tradeSEC
3 · Initial statement of ownershipApr 12, 2024Insider tradeSEC
PRE 14A · Preliminary proxy statementApr 12, 2024Meeting noticeSEC
8-K · Current reportApr 11, 2024Management or board changeSEC
4 · Change in ownershipApr 3, 2024Insider tradeSEC
4 · Change in ownershipApr 3, 2024Insider tradeSEC
S-8 · Registration statement for employee plansMar 12, 2024Offer documentSEC
10-K · Annual reportMar 12, 2024Annual reportSEC
8-K · Current reportMar 12, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedMar 11, 2024Big-stake noticeSEC
4 · Change in ownershipFeb 15, 2024Insider tradeSEC
4 · Change in ownershipFeb 15, 2024Insider tradeSEC
4 · Change in ownershipFeb 15, 2024Insider tradeSEC
4 · Change in ownershipFeb 15, 2024Insider tradeSEC
4 · Change in ownershipFeb 15, 2024Insider tradeSEC
4 · Change in ownershipFeb 15, 2024Insider tradeSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2024Big-stake noticeSEC
8-K · Current reportJan 18, 2024Management or board changeSEC
8-K · Current reportJan 4, 2024Current reportSEC
4 · Change in ownershipDec 15, 2023Insider tradeSEC
4 · Change in ownershipDec 15, 2023Insider tradeSEC
8-K · Current reportDec 13, 2023Current reportSEC
SC 13D/A · Big-stake notice, amendedNov 9, 2023Big-stake noticeSEC
10-Q · Quarterly reportNov 6, 2023Quarterly reportSEC
8-K · Current reportNov 6, 2023ResultsSEC
4 · Change in ownershipOct 19, 2023Insider tradeSEC
4 · Change in ownershipSep 18, 2023Insider tradeSEC
4 · Change in ownershipSep 18, 2023Insider tradeSEC
4 · Change in ownershipSep 18, 2023Insider tradeSEC
8-K · Current reportSep 18, 2023Management or board changeSEC
10-Q · Quarterly reportAug 11, 2023Quarterly reportSEC
8-K · Current reportAug 11, 2023ResultsSEC
4 · Change in ownershipJul 7, 2023Insider tradeSEC
4 · Change in ownershipJul 6, 2023Insider tradeSEC
4 · Change in ownershipJul 3, 2023Insider tradeSEC
8-K · Current reportJun 30, 2023Material contractSEC
424B5 · ProspectusJun 30, 2023Offer documentSEC
4 · Change in ownershipJun 29, 2023Insider tradeSEC
424B5 · ProspectusJun 29, 2023Offer documentSEC
4 · Change in ownershipJun 28, 2023Insider tradeSEC
144 · Notice of proposed saleJun 27, 2023Other filingsSEC
8-K · Current reportJun 27, 2023Current reportSEC
4 · Change in ownershipJun 16, 2023Insider tradeSEC
4 · Change in ownershipJun 16, 2023Insider tradeSEC
4 · Change in ownershipJun 16, 2023Insider tradeSEC
4 · Change in ownershipMay 17, 2023Insider tradeSEC
4 · Change in ownershipMay 17, 2023Insider tradeSEC
4 · Change in ownershipMay 17, 2023Insider tradeSEC
4 · Change in ownershipMay 17, 2023Insider tradeSEC
4 · Change in ownershipMay 17, 2023Insider tradeSEC
4 · Change in ownershipMay 17, 2023Insider tradeSEC
4 · Change in ownershipMay 17, 2023Insider tradeSEC
4 · Change in ownershipMay 17, 2023Insider tradeSEC
8-K · Current reportMay 16, 2023Meeting outcomeSEC
10-Q · Quarterly reportMay 9, 2023Quarterly reportSEC
8-K · Current reportMay 9, 2023ResultsSEC
ARS · Annual report to shareholdersApr 4, 2023Annual reportSEC
DEFA14A · Additional proxy materialApr 4, 2023Meeting noticeSEC
DEF 14A · Proxy statementApr 4, 2023Meeting noticeSEC
4 · Change in ownershipMar 20, 2023Insider tradeSEC
4 · Change in ownershipMar 20, 2023Insider tradeSEC
4 · Change in ownershipMar 20, 2023Insider tradeSEC
S-8 · Registration statement for employee plansMar 9, 2023Offer documentSEC
10-K · Annual reportMar 9, 2023Annual reportSEC
8-K · Current reportMar 9, 2023ResultsSEC
4 · Change in ownershipFeb 15, 2023Insider tradeSEC
4 · Change in ownershipFeb 15, 2023Insider tradeSEC
4 · Change in ownershipFeb 15, 2023Insider tradeSEC
4 · Change in ownershipFeb 15, 2023Insider tradeSEC
4 · Change in ownershipFeb 15, 2023Insider tradeSEC

This page holds 200 of 487 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Black Diamond Therapeutics, Inc.’s releases · as of Nov 5, 2026

Common shares
57,468,255
Fully diluted
57,468,255

Fully diluted

LineSharesAs of
Common shares57,468,255Nov 5, 2026

Share count over time

CountShares
Nov 5, 202657,468,255

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
NEA Management Company, LLC4.45M7.7%US$8.39MSep 30, 2026
BlackRock4.3M7.5%US$8.11MSep 30, 2026
T. Rowe Price3.96M6.9%US$7.47MSep 30, 2026
Vanguard2.9M5.0%US$5.46MSep 30, 2026
Acadian Asset Management LLC2.35M4.1%US$4.42MSep 30, 2026
Bank of America2.05M3.6%US$3.86MSep 30, 2026
Defilade Capital Management, L.P.1.77M3.1%US$3.34MSep 30, 2026
Renaissance Technologies1.65M2.9%US$3.11MSep 30, 2026
Geode Capital1.25M2.2%US$2.35MSep 30, 2026
Marshall Wace, LLP1.18M2.0%US$2.22MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Connor, Clark & Lunn Investment Management Ltd.1.12M2.0%US$2.12MSep 30, 2026
Dimensional956K1.7%US$1.8MSep 30, 2026
State Street943K1.6%US$1.78MSep 30, 2026
AQR Capital Management LLC890K1.5%US$1.68MSep 30, 2026
Morgan Stanley777K1.4%US$1.46MSep 30, 2026
Fidelity746K1.3%US$1.41MSep 30, 2026
Bridgeway Capital Management, LLC735K1.3%US$1.39MSep 30, 2026
Goldman Sachs688K1.2%US$1.3MSep 30, 2026
AWM Investment Company, Inc.650K1.1%US$1.23MSep 30, 2026
Northern Trust362K0.63%US$682KSep 30, 2026
Empowered Funds, LLC359K0.62%US$676KSep 30, 2026
UBS346K0.60%US$652KSep 30, 2026
BNY308K0.54%US$581KSep 30, 2026
Stifel Financial Corp289K0.50%US$546KSep 30, 2026
D. E. Shaw & Co., Inc.278K0.48%US$525KSep 30, 2026
O'Shaughnessy Asset Management, LLC167K0.29%US$316KSep 30, 2026
Banque Cantonale Vaudoise147K0.26%US$278KSep 30, 2026
Barclays144K0.25%US$271KSep 30, 2026
Schwab128K0.22%US$242KSep 30, 2026
Panagora Asset Management Inc124K0.22%US$235KSep 30, 2026
XTX Topco Ltd112K0.20%US$212KSep 30, 2026
BNP Paribas107K0.19%US$202KSep 30, 2026
CPP Investments104K0.18%US$195KSep 30, 2026
RB Capital Management, LLC100K0.17%US$189KSep 30, 2026
Balyasny Asset Management L.P.87,3130.15%US$165KSep 30, 2026
Ritholtz Wealth Management79,1830.14%US$149KSep 30, 2026
American Century78,2450.14%US$147KSep 30, 2026
Invesco69,0390.12%US$130KSep 30, 2026
Nuveen67,3870.12%US$127KSep 30, 2026
Raymond James Financial Inc67,0610.12%US$126KSep 30, 2026
Sei Investments Co58,3140.10%US$110KSep 30, 2026
Los Angeles Capital Management LLC58,0250.10%US$109KSep 30, 2026
Jane Street51,2910.09%US$96,684Sep 30, 2026
Two Sigma40,6040.07%US$76,539Sep 30, 2026
DWS40,2610.07%US$76,093Sep 30, 2026
Citigroup Inc40,1330.07%US$75,651Sep 30, 2026
HSBC37,5420.07%US$71,330Sep 30, 2026
Ieq Capital, LLC37,4910.07%US$70,671Sep 30, 2026
Susquehanna36,1470.06%US$68,137Sep 30, 2026
Rhumbline Advisers35,3830.06%US$66,693Sep 30, 2026

This page holds 50 of 107 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
T. Rowe Price Small-Cap Value Fund, Inc.2.12M3.7%US$3.92MJun 30, 2026
Vanguard Total Stock Market Index Fund1.56M2.7%US$2.88MJun 30, 2026
iShares Russell 2000 ETF1.21M2.1%US$2.24MJun 30, 2026
Fidelity Enhanced Small Cap Core ETF521K0.91%US$964KJun 30, 2026
Fidelity Small Cap Index Fund513K0.89%US$867KJul 31, 2026
Vanguard Extended Market Index Fund511K0.89%US$946KJun 30, 2026
iShares U.S. Small-Cap Equity Factor ETF469K0.82%US$793KJul 31, 2026
iShares Russell 2000 Value ETF466K0.81%US$861KJun 30, 2026
Ultra-Small Company Fund375K0.65%US$694KJun 30, 2026
iShares Biotechnology ETF347K0.60%US$642KJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
U.S. Small Cap Value Portfolio341K0.59%US$577KJul 31, 2026
EA Bridgeway Omni Small-Cap Value ETF248K0.43%US$459KJun 30, 2026
Fidelity Extended Market Index Fund240K0.42%US$534KMay 31, 2026
Dimensional US Small Cap Value ETF210K0.37%US$355KJul 31, 2026
Small Cap Value Portfolio183K0.32%US$338KJun 30, 2026
iShares Micro-Cap ETF159K0.28%US$295KJun 30, 2026
Schwab Small-Cap Index Fund114K0.20%US$192KJul 31, 2026
T. Rowe Price Spectrum Moderate Growth Allocation Fund96,0290.17%US$213KMay 31, 2026
Invesco RAFI US 1500 Small-Mid ETF94,1810.16%US$159KJul 31, 2026
Small Company Growth Portfolio93,1800.16%US$172KJun 30, 2026
Master Small Cap Index Series88,2230.15%US$163KJun 30, 2026
Ultra-Small Company Market Fund88,0000.15%US$163KJun 30, 2026
WisdomTree U.S. SmallCap Fund85,3800.15%US$158KJun 30, 2026
Fidelity Total Market Index Fund78,9810.14%US$175KMay 31, 2026
U.S. Small Cap Portfolio74,3160.13%US$126KJul 31, 2026
Avantis U.S. Small Cap Equity ETF73,6540.13%US$164KMay 31, 2026
Omni Small-Cap Value Fund70,0000.12%US$130KJun 30, 2026
U.S. Micro Cap Portfolio69,3820.12%US$117KJul 31, 2026
Fidelity Series Total Market Index Fund67,2720.12%US$149KMay 31, 2026
Fidelity Small Cap Value Index Fund65,6600.11%US$121KJun 30, 2026
Nuveen Small Cap Blend Index Fund64,8010.11%US$110KJul 31, 2026
Dimensional U.S. Small Cap ETF62,4350.11%US$106KJul 31, 2026
VIP Disciplined Small Cap Portfolio53,3190.09%US$98,640Jun 30, 2026
EQ/2000 Managed Volatility Portfolio52,6160.09%US$97,340Jun 30, 2026
Small Company Value Trust40,6000.07%US$75,110Jun 30, 2026
LVIP State Street Small-Cap Index Fund38,4000.07%US$71,040Jun 30, 2026
Dimensional U.S. Core Equity 2 ETF35,7610.06%US$60,436Jul 31, 2026
Fidelity Nasdaq Composite Index Fund32,4980.06%US$72,146May 31, 2026
T. Rowe Price Spectrum Moderate Allocation Fund31,0740.05%US$68,984May 31, 2026
Vanguard Institutional Total Stock Market Index Fund30,7690.05%US$56,923Jun 30, 2026
Vanguard Balanced Index Fund27,0000.05%US$49,950Jun 30, 2026
Fidelity ZERO Total Market Index Fund23,6430.04%US$39,957Jul 31, 2026
Global X Russell 2000 ETF22,5310.04%US$38,077Jul 31, 2026
Small Cap Index Fund21,8360.04%US$40,397Jun 30, 2026
T. Rowe Price Spectrum Conservative Allocation Fund21,1710.04%US$47,000May 31, 2026
Goldman Sachs Absolute Return Tracker Fund20,2010.04%US$37,372Jun 30, 2026
Small-Cap Index Portfolio16,6580.03%US$30,817Jun 30, 2026
EQ/Small Company Index Portfolio16,1700.03%US$29,915Jun 30, 2026
EQ/AB Small Cap Growth Portfolio16,1700.03%US$29,915Jun 30, 2026
Fidelity ZERO Extended Market Index Fund15,8070.03%US$26,714Jul 31, 2026

This page holds 50 of 93 holders. Open Shareholders

Big stakes

StakeStakeSharesDateFiling
T. Rowe Price Investment Management, Inc.7.00%4.03MJun 30, 2026Schedule 13G
BlackRock, Inc.6.70%3.84MJun 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Rajeev M Shah
Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Wave Life Sciences Ltd. (Director · Since at least Aug 16, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Forma Therapeutics Holdings Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); POINT Biopharma Global Inc (Director · Jun 23, 2021 – Jun 29, 2021 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – May 27, 2020 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 17, 2021 · Past); KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past)
Director · Jan 29, 2020 – Jul 5, 2023 · Past
Ali Behbahani
Other companies: SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); NeueHealth Inc (Director · Since at least Oct 2, 2025); Korro Bio, Inc. (Director · Since at least Nov 3, 2023); Arcellx Inc (Director · Since at least Feb 3, 2022); Monte Rosa Therapeutics, Inc. (Director · Since at least Jun 23, 2021); Nkarta, Inc. (Director · Since at least Jul 9, 2020); Adaptimmune Therapeutics PLC (Director · Since at least Jul 2, 2019); CRISPR Therapeutics AG (Director · Since at least Jun 11, 2019); Minerva Surgical, Inc. (Director · Oct 21, 2021 – Jun 10, 2022 · Past); CVRx, Inc. (Director · Jun 29, 2021 – Jun 4, 2024 · Past); Oyster Point Pharma Inc (Director · Oct 30, 2019 – Jan 3, 2023 · Past)
Director · Since at least Jan 29, 2020
Garry E. Menzel
Other companies: Adaptimmune Therapeutics PLC (Non-Executive Director · Since at least Jun 1, 2023); Stoke Therapeutics, Inc. (Director · Since at least Aug 13, 2020); Tcr2 Therapeutics Inc (President and CEO, Director · Feb 13, 2019 – Jun 1, 2023 · Past); DaVita Inc. (Senior Vice President, Finance · Sep 9, 2013 – Sep 9, 2013 · Past); Regulus Therapeutics Inc (COO & Executive VP, Finance · Oct 4, 2012 – Dec 11, 2012 · Past)
Operating Partner, GHO Capital Partners LLP · Since at least Jan 29, 2020
Kapil Dhingra
Other companies: LAVA Therapeutics NV (Director · Since at least Jan 1, 2025); CARGO Therapeutics, Inc. (Director · Since at least Apr 15, 2024); Replimune Group, Inc. (Director · Since at least Jul 19, 2018); Five Prime Therapeutics Inc (Director · Dec 2, 2015 – Apr 16, 2021 · Past)
Director · Since at least Jan 19, 2021
Samarth Kulkarni
Other companies: Oruka Therapeutics, Inc. (Director · Since at least Aug 29, 2024); Centessa Pharmaceuticals PLC (Director · Since at least May 27, 2021); CRISPR Therapeutics AG (Chief Executive Officer and Chairman of the Board · Since at least Oct 18, 2016); Repare Therapeutics Inc (Director · Jun 18, 2020 – Jun 17, 2024 · Past)
CEO, CRISPR Therapeutics AG · Since at least Jan 29, 2020
Rachel Humphrey
Other companies: Pyxis Oncology, Inc. (Director · Since at least Aug 11, 2022); Xilio Therapeutics, Inc. (Director · Oct 21, 2021 – Oct 21, 2021 · Past)
Chief Medical Officer · Feb 17, 2021 – Feb 17, 2021 · Past
Sergey Yurasov
Other companies: Nuvation Bio Inc. (Chief Medical Officer · Feb 10, 2021 – Feb 10, 2021 · Past); Immune Design Corp (Sr. VP, Clinic. Devel. & CMO · Oct 1, 2016 – Apr 2, 2019 · Past)
CHIEF MEDICAL OFFICER · Since at least Jun 10, 2022
David M Epstein
Other companies: Gyre Therapeutics, Inc. (Director · Since at least Aug 6, 2024)
SEE REMARKS, Director · Jan 29, 2020 – Jun 27, 2023 · Past
Mark A. Velleca
Other companies: G1 Therapeutics Inc (Director · May 16, 2017 – Aug 8, 2023 · Past)
Chief Executive Officer · Since at least Aug 9, 2021
Prakash Raman
Other companies: Olema Pharmaceuticals, Inc. (Director · Since at least Apr 28, 2026)
CEO of InduPro, Inc. · Since at least Apr 10, 2024
All 17 people
PersonSeat
Brent Hatzis-SchochChief Operating Officer, General Counsel · Since at least Nov 5, 2026
Elizabeth BuckCo-Founder, Chief Scientific Officer · Since at least Sep 15, 2021
Elizabeth L. MontgomeryChief People Officer · Jan 28, 2026 – Nov 5, 2026 · Past
Erika JonesSenior Vice President of Finance and Principal Financial & Accounting Officer · Since at least Nov 18, 2021
Fang NiSEE REMARKS · Nov 18, 2021 – Feb 14, 2024 · Past
Melanie MorrisonChief Development Officer · Since at least Nov 5, 2026
Shannon CampbellDirector · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Black Diamond Therapeutics, Inc.